ICPB H is developed by Cairo University.

What development phase is ICPB H in?

ICPB H is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

ICPB H

Cairo University · FDA-approved active Small molecule Quality 1/100

ICPB H, developed by Cairo University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant period of exclusivity. The lack of detailed revenue and competitive landscape data poses a primary risk in assessing its market strength and potential threats.

At a glance

Generic name	ICPB H
Sponsor	Cairo University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Analgesic Efficacy of Intermediate Cervical Plexus Block in Patients Undergoing Neck Surgeries: A Comparison Between Two Bupivacaine Concentrations (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ICPB H CI brief — competitive landscape report
ICPB H updates RSS · CI watch RSS
Cairo University portfolio CI